In This Section

Program: Tuesday, July 21

Wednesday, July 22 Thursday, July 23 Friday, July 24

Please note that this meeting will take place as an in-person event in Boston, Massachusetts and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

Tuesday, July 21

Tuesday, July 21

REGISTRATION

12-9 p.m. | Grand Ballroom Prefunction

Educational Sessions 1-2

2:30-5:30 p.m.

Educational Session 1: Global Drug Discovery and Development: Progress, Challenges, and the Path Forward

Constitution Ballroom A

Session Chair: To be announced

  • Geetika Srivastava, U.S. Food and Drug Administration, Silver Spring, Maryland
  • Caicun Zhou, Tongi University, Shanghai, China
  • Takafumi Koyama, National Cancer Center Japan, Tokyo, Japan
  • Anthony Joshua, Garvan Institute of Medical Research, Sydney, NSW, Australia
  • Mike Sathekge, University of Pretoria, Pretoria, South Africa
  • Paulo M. Hoff, University of Sao Paulo, Sao Paulo, Brazil
  • Seock-Ah Im, Seoul National University, Seoul, Korea  

Educational Session 2: Case Studies in Drug Discovery and Development

Constitution Ballroom B

Session Chair: Norbert Kraut, Boehringer Ingelheim, Vienna, Austria

  • 3:30 p.m. | Introduction
  • 3:40 p.m. | Zongertinib (irreversible HER2 TKI for HER2mut+ nsqNSCLC)
    Preclinical     – Ralph A. Neumüller, Boehringer Ingelheim, Vienna, Austria
    Clinical – John V. Heymach, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 4:15 p.m. | Ziftomenib (menin inhibitor for NPM1-mutated AML)
    Preclinical     – Francis Burrows, Kura Oncology, San Diego, California
    Clinical – Eunice S. Wang, Roswell Park Comprehensive Cancer Center, Roswell Park, New York
  • 4:50 p.m. | Datopotamab Deruxtecan (Dato-DXd) (TROP2-targeted ADC for the treatment of hormone receptor-positive, HER2-negative breast cancer)
    Preclinical     – Speaker to be announced
    Clinical – Aditya Bardia, UCLA David Geffen School of Medicine, Los Angeles, California

Welcome and Opening Keynote Lectures

6-8 p.m. | Grand Ballroom

  • 6 p.m. | Welcome and Introductory Remarks
    Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canads
  • 6:10 p.m. | Introduction of Keynote Speaker
    Keith T. Flaherty, Harvard Medical School, Boston, Massachusetts
  • 6:15 p.m. | Keynote
    Alexis Borisy, Curie.Bio, Boston, Massachusetts
  • 6:30 p.m. | Introduction of Keynote Speaker
    Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 6:35 p.m. | Keynote
    Chris Boshoff, Pfizer, New York, New York
  • 6:50 p.m. | Introduction of Keynote Speaker
    Patricia M. LoRusso, Yale School of Medicine, New Haven, Connecticut
  • 6:55 p.m. | Keynote to be announced
  • 7:10 p.m. | Panel Discussion

Opening Reception

8:15-10 p.m. | Back Bay Ballroom